Alle verbonden artikelen

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Auteurs : Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber Rd, Piccart-Gebhart M, Cameron D
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(3)
Pagina's : 244-8

The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Auteurs : Klastersky J, Paesmans M
Jaar : 2013
Journal : Support Care Cancer
Volume : 21(5)
Pagina's : 1487-95

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Auteurs : Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M
Jaar : 2013
Journal : Breast
Volume : 22 Suppl 2
Pagina's : S152-5

Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study.

Auteurs : Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scalliet P, Cornette P, Pepersack T, Luce S, Langenaeken C, Rasschaert M, Allepaerts S, Van Rijswijk R, Milisen K, Flamaing J, Lobelle JP, Wildiers H
Jaar : 2013
Journal : Ann Oncol
Volume : 24(5)
Pagina's : 1306-12

The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.

Auteurs : Klastersky J, Raftopoulos H, Rapoport B
Jaar : 2013
Journal : Support Care Cancer
Volume : 21(6)
Pagina's : 1793-5

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis.

Auteurs : Azim HA, Singhal S, Ignatiadis M, Desmedt C, Fumagalli D, Veys I, Larsimont D, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2013
Journal : PLoS One
Volume : 8(4)
Pagina's : e62451

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Auteurs : Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, Orlandi F, Gravis G, Matveev V, Bavbek S, Gil T, Viana L, Arén O, Karyakin O, Elliott T, Birtle A, Magherini E, Hatteville L, Petrylak D, Tombal B, Rosenthal M
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(8)
Pagina's : 760-8

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).

Auteurs : Ades F, de Azambuja E, Daugaard G, Ameye L, Moulin C, Paesmans M, De Jong D, Decoster L, De Greve J, Ismael G, Møller AK, Piccart-Gebhart M, Awada A
Jaar : 2013
Journal : J Chemother
Volume : 25(4)
Pagina's : 239-46

Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.

Auteurs : Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A
Jaar : 2013
Journal : Invest New Drugs
Volume : 31(4)
Pagina's : 959-66

Planning cancer control in Latin America and the Caribbean.

Auteurs : Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, Louis JS, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Dueñas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabús R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernández A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G
Jaar : 2013
Journal : Lancet Oncol
Volume : 14(5)
Pagina's : 391-436

Imbalance between supply and need of medical oncologists in Belgium

Auteurs : Dhondt V, Benahmed A, De Wever L, Dirix L, de Valeriola D
Jaar : 2013
Journal : Belgian J Medical Oncology
Volume : 7(2)
Pagina's : 38-45

Understanding the factors associated with the surgical management of early breast cancer.

Auteurs : Youssef OZ, Azim HA
Jaar : 2013
Journal : Gland Surg
Volume : 2(1)
Pagina's : 4-6

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

Auteurs : Criscitiello C, Azim HA, Agbor-Tarh D, de Azambuja E, Piccart-Gebhart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT
Jaar : 2013
Journal : Ann Oncol
Volume : 24(8)
Pagina's : 1980-5

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer.

Auteurs : Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S
Jaar : 2013
Journal : Clin Cancer Res
Volume : 19(1)
Pagina's : 28-33

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.

Auteurs : Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M
Jaar : 2013
Journal : Breast Cancer Res. Treat.
Volume : 139(1)
Pagina's : 13-22

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. (published online 11/2012)

Auteurs : Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, Messina C, Paoletti C, Müller V, Hayes DF, Piccart-Gebhart M, Pierga JY
Jaar : 2013
Journal : Cancer Metastasis Rev
Volume : 32(1-2
Pagina's : 179-88

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Auteurs : Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart M
Jaar : 2013
Journal : Cancer Treat Rev
Volume : 39(8)
Pagina's : 935-46

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Auteurs : Peccatori FA, Azim HA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G
Jaar : 2013
Journal : Ann Oncol
Volume : 24 Suppl 6
Pagina's : vi160-70

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Auteurs : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Jaar : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pagina's : 734-41

Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial.

Auteurs : Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber Rd, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M
Jaar : 2013
Journal : J. Clin. Oncol.
Volume : 31(16)
Pagina's : 1954-60